Company profile
Lisata Therapeutics, Inc.
NASDAQ: LSTA · Healthcare · Biotechnology
#1020 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
39DFH 26DQ 61GM 27SS 57
v0.1 · 65/100 weight · provisional
↑ listing tenure, balance-sheet leverage · ↓ Piotroski F, operating margin
Methodology →Revenue TTM
$170.0k
Rev growth YoY (TTM)
-83.0%
Net income (FY)
-$16.6M
Employees
21
as of 2026-08-20
Market cap
$10.2M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$170.0k$170.0k2024
Net income-$16.6M-$16.6M2024
Operating income-$18.2M-$18.2M2024
Total assets$17.7M$17.7M2024
Liabilities$3.1M$3.1M2024
Equity$14.9M$14.9M2024
Revenue trend
FY2015 – FY2024 · USD
FY15
FY15
FY15
FY16
FY23
FY23
FY24
FY24
Revenue by segment
Filed disclosures · FY2025
By product
Reportable100%
By geography
Not disclosed.
The read
What is Lisata Therapeutics, Inc.’s revenue?
Lisata Therapeutics, Inc. booked $170.0k in FY2024 revenue, contracting 83% year over year — slower than 89% of Healthcare companies we track, at a -9756.5% net margin.
Peers · Healthcare
Appili Therapeutics Inc28DMedMira Inc.31DEden Empire Inc.——InnerScope Hearing Technologies, Inc.——Kalaris Therapeutics Inc30DCurative Biosciences, Inc.——Neighbors
Somerset →Key facts
CEODavid J. Mazzo
SectorHealthcare
IndustryBiotechnology
HeadquartersBasking Ridge, NJ
ExchangeNASDAQ: LSTA
Employees21
IPO date1999-03-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.